Aduro Biotech is an immunotherapy company focused on the discovery, development and commercialization of therapies for treament of diseases, including cancer. Product candidates from Co.'s STING Pathway Activator, B-select monoclonal antibody, and Live, Attenuated, Double-Deleted Listeria monocytogenes platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies as well as other immunotherapies. Co.'s STING Pathway technology platform include its main molecule ADU-S100, which targets STING. Co. is also in preclinical development of a CTLA-4 checkpoint inhibitor blocking antibody. We show 18 historical shares outstanding datapoints in our coverage of ADRO's shares outstanding history.
Understanding the changing numbers of ADRO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADRO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADRO by allowing them to research ADRO shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
